This opportunity funds institutions to serve as Lead Academic Organizations in the Experimental Therapeutics Clinical Trials Network. LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials involving investigational agents under NCI regulatory sponsorship. LAOs collaborate within the network to advance experimental therapeutics through phase 0, 1, 2, and pilot clinical trials.
Eligible applicants include a wide range of U.S. institutions such as public and private higher education institutions, nonprofits, for-profit organizations (excluding small businesses), government entities, tribal governments and organizations, and independent school districts.
